BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?

被引：0
作者：
Guerrero-Ramos, F. [1 ,2 ,3 ]
机构：
[1] Hosp Univ 12 Octubre, Serv Urol, Unidad Urooncol, Madrid, Spain
[2] ROC Clin, Madrid, Spain
[3] Hosp Univ HM Sanchinarro, Madrid, Spain
来源：
ACTAS UROLOGICAS ESPANOLAS | 2023年 / 47卷 / 06期
关键词：
BACILLUS-CALMETTE-GUERIN; CARCINOMA IN-SITU; VALRUBICIN; FAILURE;
D O I：
10.1016/j.acuro.2023.01.004
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：329 / 331
页数：3
相关论文
共 15 条
  • [1] Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)
    Alvarez-Maestro, M.
    Guerrero-Ramos, F.
    Rodriguez-Faba, O.
    Dominguez-Escrig, J. L.
    Fernandez-Gomez, J. M.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (02): : 93 - 102
  • [2] European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
    Babjuk, Marko
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Escrig, Jose L. Dominguez
    Gontero, Paolo
    Liedberg, Fredrik
    Masson-Lecomte, Alexandra
    Mostafid, A. Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Roupret, Morgan
    Shariat, Shahrokh F.
    Seisen, Thomas
    Soukup, Viktor
    Sylvester, Richard J.
    [J]. EUROPEAN UROLOGY, 2022, 81 (01) : 75 - 94
  • [3] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    Balar, Arjun, V
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Li, Haojie
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    de Wit, Ronald
    [J]. LANCET ONCOLOGY, 2021, 22 (07) : 919 - 930
  • [4] Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
    Boorjian, Stephen A.
    Alemozaffar, Mehrdad
    Konety, Badrinath R.
    Shore, Neal D.
    Gomella, Leonard G.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Busby, Joseph E.
    Poch, Michael
    Crispen, Paul L.
    Steinberg, Gary D.
    Schuckman, Anne K.
    Downs, Tracy M.
    Svatek, Robert S.
    Mashni, Joseph, Jr.
    Lane, Brian R.
    Guzzo, Thomas J.
    Bratslavsky, Gennady
    Karsh, Lawrence I.
    Woods, Michael E.
    Brown, Gordon
    Canter, Daniel
    Luchey, Adam
    Lotan, Yair
    Krupski, Tracey
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Keegan, Kirk A.
    Andriole, Gerald L., Jr.
    Sankin, Alexander I.
    Boyd, Alan
    O'Donnell, Michael A.
    Sawutz, David
    Philipson, Richard
    Coll, Ruth
    Narayan, Vikram M.
    Treasure, F. Peter
    Yla-Herttuala, Seppo
    Parker, Nigel R.
    Dinney, Colin P. N.
    [J]. LANCET ONCOLOGY, 2021, 22 (01) : 107 - 117
  • [5] Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
    Catto, James W. F.
    Gordon, Kathryn
    Collinson, Michelle
    Poad, Heather
    Twiddy, Maureen
    Johnson, Mark
    Jain, Sunjay
    Chahal, Rohit
    Simms, Matt
    Dooldeniya, Mohantha
    Bell, Richard
    Koenig, Phillip
    Conroy, Samantha
    Goodwin, Louise
    Noon, Aidan P.
    Croft, Julie
    Brown, Julia M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 202 - +
  • [6] Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin
    Dinney, Colin P. N.
    Greenberg, Richard E.
    Steinberg, Gary D.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (08) : 1635 - 1642
  • [7] Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
    Guerrero-Ramos, Felix
    Gonzalez-Padilla, Daniel A.
    Gonzalez-Diaz, Alejandro
    de la Rosa-Kehrmann, Federico
    Rodriguez-Antolin, Alfredo
    Inman, Brant A.
    Villacampa-Auba, Felipe
    [J]. WORLD JOURNAL OF UROLOGY, 2022, 40 (04) : 999 - 1004
  • [8] Lessons Learned From 1,000 Neobladders: The 90-Day Complication Rate
    Hautmann, Richard E.
    de Petriconi, Robert C.
    Volkmer, Bjoern G.
    [J]. JOURNAL OF UROLOGY, 2010, 184 (03) : 990 - 994
  • [9] Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
    Kamat, Ashish M.
    Sylvester, Richard J.
    Bohle, Andreas
    Palou, Joan
    Lamm, Donald L.
    Brausi, Maurizio
    Soloway, Mark
    Persad, Raj
    Buckley, Roger
    Colombel, Marc
    Witjes, J. Alfred
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1935 - +
  • [10] An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
    Malmstrom, Per-Uno
    Sylvester, Richard J.
    Crawford, David E.
    Friedrich, Martin
    Krege, Susanne
    Rintala, Erkki
    Solsona, Eduardo
    Di Stasi, Savino M.
    Witjes, J. Alfred
    [J]. EUROPEAN UROLOGY, 2009, 56 (02) : 247 - 256
12